Recursion Pharmaceuticals Inc (NASDAQ:RXRX) at last check was buoying at $10.05 on current market day with a fall of -7.59% from its closing price on previous day.
Considering stock’s 52-week price range provides that RXRX hit a high price of $15.74 and saw its price falling to a low level of $5.60 during that period. Over a period of past 1-month, stock came adding 46.00% in its value.
With its current market valuation of $3.93 billion, Recursion Pharmaceuticals Inc is set to declare its quarterly results in March. Analysts are in estimates of -0.42 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -1.54 for current year with estimates of that growing to -1.64 in next year.
Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of 19.04M. They suggested that in the process company could generate revenue of as low as 8M which could climb up to 40.1M to hit a high. The average estimate is representing an increase of 74.85% in sales growth from that of posted by the company in the same quarter of last year. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of 67.8M in current fiscal year, which will be 52.11% more from revenue generated by the company last year.
In contrast, when we review RXRX stock’s current outlook then short term indicators are assigning it an average of 100% Buy, while medium term indicators are categorizing the stock at an average of 100% Buy. Long term indicators are suggesting an average of 50% Buy for it.
According to ratings assigned by 3 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; 1 of them are recommending Recursion Pharmaceuticals Inc (RXRX) as a Hold, while 2 are in view that stock is a Buy. Recommendation by 0 analysts for the stock is an Underweight while number of those analysts who rated the stock as an Overweight is 0, whereas 0 of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Overweight and that encourages the investors to exploit the opportunity and build their stake up in the company.
Digging deeper we become aware of the PEG ratio of the RXRX stock which is currently positioned at 0. It further provides that stock’s current price level is 23.13% away from its 20-day simple moving average and is 33.77% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 66.21 while volatility remained at 14.52% over the past week which changes to 10.78% when measuring it over the past month. Beta is valued at 0.90, while measure of average true range or ATR is currently at 0.96. In predicting price targets of as low as $6 and as high as $12, analysts are in agreement on assigning the stock over the next 12 months average price target of $11. Stock’s current price level is 40.3% above from estimated low price target while it is -19.4% below the estimated high; and even if the RXRX’s share succeeded to reach the median price of $11, then the outlook of -9.45% could come to the excitement of the investors.
The percentage of outstanding shares held by the insiders is 24.01% while it is 61.89% for the institutional holders. Addition of 48.59% by stock’s current price to its year-to-date value in today’s trading is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.
